Celecoxib Capsules
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-26-D-0010
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Defense Logistics Agency (DLA) Troop Support, a federal office under the Department of Defense, has issued an award notice for the procurement of Celecoxib Capsules under contract number SPE2D2-26-D-0010. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, indicating drugs and biologicals.
The primary objective of this procurement is to ensure a reliable supply of Celecoxib Capsules, a pharmaceutical product commonly used for pain management and inflammation reduction, to support the operational readiness and healthcare needs of military personnel and associated beneficiaries. The scope of the contract encompasses the manufacturing and delivery of Celecoxib Capsules to the designated place of performance in Hauppauge, New York, United States. The contract is intended to guarantee the availability of this essential medication, thereby contributing to the overall mission of the Department of Defense to maintain the health and effectiveness of its forces.
Key requirements for this contract include adherence to all applicable pharmaceutical manufacturing standards and regulations, ensuring product quality, safety, and efficacy. The contractor is expected to deliver Celecoxib Capsules in accordance with the specifications outlined by DLA Troop Support, with timely and consistent fulfillment of orders as a critical deliverable. While the specific quantities and delivery schedules are not detailed in the notice, contractors should anticipate the need for robust production and distribution capabilities to meet the demands of the Department of Defense.
This procurement is not subject to any set-aside restrictions, meaning it is open to all qualified offerors without preference for small businesses or other socioeconomic categories. The contract is managed by DLA Troop Support, with primary and secondary points of contact provided for further inquiries: Ryan Guarnere ([email protected], 445-737-1729) and Jason Wray ([email protected], 445-737-6304).
Contractors considering this opportunity should possess proven experience in pharmaceutical preparation manufacturing, particularly in the production of nonsteroidal anti-inflammatory drugs (NSAIDs) like Celecoxib. Compliance with federal acquisition regulations and the ability to meet stringent quality assurance standards are essential. The place of performance is specified as Hauppauge, New York, which may influence logistical planning and distribution strategies.
The notice remains active as of the posting date, March 19, 2026, and further details, including any attachments, can be accessed via the official SAM.gov opportunity listing (Opportunity ID: da23bd0b326b419caa0e7a99495ddfa2).
In summary, this award notice represents a significant opportunity for pharmaceutical manufacturers with the capacity to supply high-quality Celecoxib Capsules to the Department of Defense, supporting critical healthcare operations for military personnel.